NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01381809,An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes,https://clinicaltrials.gov/study/NCT01381809,,COMPLETED,The purpose of this study is to demonstrate that epoetin alfa works better than placebo in improving anemia in patients with lower-risk myelodysplastic syndromes (MDS). The safety of epoetin alfa will also be evaluated.,NO,Myelodysplastic Syndromes,DRUG: Group 2: Placebo|DRUG: Group 1: Epoetin alfa,"Erythroid response, at week 24","Maintenance of Erythroid response, every 4 weeks from week 24 to week 48|Duration of response, every 4 weeks after week 24|Time to first Red Blood Cell transfusion, from baseline to study end (week 28 for non responders, week 54 for responders or 4 weeks after early withdrawal)|Transfusion-free intervals, from baseline to study end (week 28 for non responders, week 54 for responders or 4 weeks after early withdrawal)|Number of Red Blood Cell units transfused, from baseline to study end (week 28 for non responders, week 54 for responders or 4 weeks after early withdrawal)|Quality of life as measured by Functional Assessment of Cancer Therapy-Anemia/Fatigue (FACT-An) questionnaire, at baseline, week 24 and week 48|Quality of life as measured by EuroQol 5-dimension (EQ-5D) questionnaire, at baseline, week 24 and week 48|Drug consumption, every 4 weeks from baseline to week 48|Duration of hospitalization, every 4 weeks from baseline to week 48|Number and duration of medical care encounters, every 4 weeks from baseline to week 48",,Janssen-Cilag International NV,,ALL,"ADULT, OLDER_ADULT",PHASE3,130,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",CR018367|EPOANE3021|2010-022884-36,2011-10,2015-01,2016-01,2011-06-27,,2016-03-16,"Plovdiv, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Amiens, France|Angers Cedex 9, France|Bobigny, France|Colmar, France|Paris Cedex 10, France|Pessac Cedex, France|Pierre Benite Cedex, France|Saint Priest En Jarez, France|Tours Cedex 9, France|Vandoeuvre Les Nancy, France|Berlin, Germany|Dresden, Germany|Duisburg, Germany|Düsseldorf, Germany|Dÿsseldorf, Germany|München, Germany|Oldenburg, Germany|Würzburg, Germany|Athens, Greece|Goudi-Athens, Greece|Larisa, Greece|Patra, Greece|Thessalonikis, Greece|Ekaterinburg, Russian Federation|St. Petersburg, Russian Federation",
